Search

Search Constraints

You searched for: Author/Creator Barbarini, G.

Search Results

1. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

2. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group. (10th February 2016)

4. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Issue 1 (16th February 2017)

5. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network. Issue 1 (16th February 2017)